American Heart Journal
Volume 152, Issue 5 , Pages 997-1003 , November 2006

Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death

  • Heidi T. May, MSPH

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • ,
  • Benjamin D. Horne, PhD, MPH

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • ,
  • Jeffrey L. Anderson, MD, FACC

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • Cardiology Division, University of Utah, Salt Lake City, UT
    • ,
  • Robert L. Wolfert, PhD

      Affiliations

    • diaDexus Inc, San Francisco, CA
    • ,
  • Joseph B. Muhlestein, MD, FACC

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • Cardiology Division, University of Utah, Salt Lake City, UT
    • ,
  • Dale G. Renlund, MD, FACC

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • Cardiology Division, University of Utah, Salt Lake City, UT
    • ,
  • Jessica L. Clarke

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • ,
  • Matthew J. Kolek, BS

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • ,
  • Tami L. Bair, BS

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • ,
  • Robert R. Pearson, BS

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • ,
  • Krishnankutty Sudhir, MD, PhD

      Affiliations

    • diaDexus Inc, San Francisco, CA
    • ,
  • John F. Carlquist, PhD

      Affiliations

    • Cardiovascular Department, LDS Hospital, Salt Lake City, UT
    • Cardiology Division, University of Utah, Salt Lake City, UT
    • Corresponding Author InformationReprint requests: John F. Carlquist, PhD, Cardiovascular Department, LDS Hospital, 8th Avenue and C Street, Salt Lake City, UT 84143.

Received 3 August 2005 ,Accepted 25 January 2006.

References 

  1. American Heart Association . Heart disease and stroke statistical update. Dallas (Tex): American Heart Association; 2004;
  2. Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–298
  3. Khot MB, Bajzer CT, Sapp SK, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898–904
  4. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–1565
  5. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently health men. N Engl J Med. 1997;336:973–979
  6. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham coronary heart disease risk score. Circulation. 2003;108:161–165
  7. Ridker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation. 2004;109:1955–1959
  8. Bogaty P, Brophy JM, Boyer L, et al. Fluctuating inflammatory markers in patients with stable ischemic heart disease. Arch Intern Med. 2005;165:221–226
  9. Packard CJ, O'Reilly DSJ, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148–1155
  10. Koenig W, Khuseyinova N, Löwel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population. Circulation. 2004;110:1903–1908
  11. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2004;109:837–842
  12. Brilakis ES, McConnell JP, Lennon RJ, et al. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005;26:137–144
  13. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001;1:121–125
  14. Macphee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999;3338(Pt 2):479–487
  15. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340:115–126
  16. Carpenter KL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidized LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357–363
  17. Rexrode KM, Lee IM, Cook NR, et al. Baseline characteristics of participants in the women's health study. J Women's Health Gend Based Med. 2000;9:19–27
  18. Anonymous . Myocardial infarction and mortality in the Coronary Artery Surgery Study (CASS) randomized trial. N Engl J Med. 1984;310:750–758
  19. Caslake MJ, Packard CJ, Suckling KE, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413–419
  20. Clarke JL, Anderson JL, Carlquist JF, et al. Comparison of differing C-reactive protein assay methods and their impact on cardiovascular risk assessment. Am J Cardiol. 2005;95:155–158
  21. Ridker PM, Glynn RJ, Hennekens CH. C-Reactive protein adds to the predictive value of total HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97:2007–2011
  22. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation. 1999;100:230–235
  23. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001;1:121–125

 We gratefully acknowledge the financial support of diaDexus Inc, San Francisco, CA.

PII: S0002-8703(06)00064-0

doi: 10.1016/j.ahj.2006.01.011

American Heart Journal
Volume 152, Issue 5 , Pages 997-1003 , November 2006

Article Tools

* Image Usage & Resolution